A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.

MAbs 2015 ;7(5):931-45

a Antibody Technology; Eli Lilly and Company ; New York , NY USA.

Bi-specific antibodies (BsAbs), which can simultaneously block 2 tumor targets, have emerged as promising therapeutic alternatives to combinations of individual monoclonal antibodies. Here, we describe the engineering and development of a novel, human bi-functional antibody-receptor domain fusion molecule with ligand capture (bi-AbCap) through the fusion of the domain 2 of human vascular endothelial growth factor receptor 1 (VEGFR1) to an antibody directed against insulin-like growth factor - type I receptor (IGF-IR). The bi-AbCap possesses excellent stability and developability, and is the result of minimal engineering. Beyond potent neutralizing activities against IGF-IR and VEGF, the bi-AbCap is capable of cross-linking VEGF to IGF-IR, leading to co-internalization and degradation of both targets by tumor cells. In multiple mouse xenograft tumor models, the bi-AbCap improves anti-tumor activity over individual monotherapies. More importantly, it exhibits superior inhibition of tumor growth, compared with the combination of anti-IGF-IR and anti-VEGF therapies, via powerful blockade of both direct tumor cell growth and tumor angiogenesis. The unique "capture-for-degradation" mechanism of the bi-AbCap is informative for the design of next-generation bi-functional anti-cancer therapies directed against independent signaling pathways. The bi-AbCap design represents an alternative approach to the creation of dual-targeting antibody fusion molecules by taking advantage of natural receptor-ligand interactions.

Download full-text PDF

Source
http://dx.doi.org/10.1080/19420862.2015.1055442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623440PMC
June 2016
113 Reads

Publication Analysis

Top Keywords

growth factor
8
antibody-receptor domain
8
igf-ir vegf
8
bi-functional antibody-receptor
8
domain fusion
8
tumor
6
bi-abcap
6
activities igf-ir
4
engineering potent
4
neutralizing activities
4
anti-cancer therapies
4
potent neutralizing
4
vegf bi-abcap
4
therapies directed
4
capable cross-linking
4
next-generation bi-functional
4
leading co-internalization
4
co-internalization degradation
4
igf-ir leading
4
vegf igf-ir
4

Altmetric Statistics

References

(Supplied by CrossRef)

Kontermann RE et al.
Drug Dis Today 2015

Similar Publications